Concord Biotech has agreed to acquire a 27.38% equity stake in FSGE Renewable Power Private Limited for ₹6.3 crore to develop a wind-solar hybrid power project. The investment aims to supply renewable energy to the company's Limbasi Facility in Gujarat, featuring a wind capacity of approximately 6.3 MW AC and a solar capacity of approximately 6.3 MWp DC. This transition to renewable energy is intended to reduce the company's carbon footprint and lower long-term energy costs, reinforcing its commitment to environmental responsibility and operational efficiency.

The acquisition will be made through a cash consideration of ₹6.3 crore, to be paid in one or more tranches. Following the acquisition, FSGE will become an associate of Concord Biotech Limited, categorizing the investment as a Related Party Transaction. The company confirmed that the transaction will be conducted at arm's length, and none of the promoter, promoter group, or group companies hold any interest in the target entity.

FSGE Renewable Power Private Limited was incorporated on August 19, 2023, as a Special Purpose Vehicle for captive power generation through renewable energy. The entity has not yet commenced commercial operations. Its authorized and paid-up share capital stands at ₹1,00,000, divided into 10,000 equity shares of ₹10 each as on June 15, 2026.

Transaction Details

The requisite details regarding the acquisition have been submitted to the exchanges in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The equity shares against the current investment are expected to be allotted within 60 days from the date of the agreement.

Officials from Concord Biotech will meet investors in Mumbai on June 24 and 25, 2026, during a Non-Deal Roadshow organised by Kotak Institutional Equities. The meetings provide an opportunity for analysts and institutional investors to engage with the company's management. Discussions will be restricted to publicly available information, ensuring no unpublished price sensitive information (UPSI) is shared.

The regulatory filing was submitted to the exchanges in compliance with Regulation 30(6) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015. The company noted that the schedule remains subject to changes due to exigencies on the part of the participants or the company.

The schedule for the investor meetings is as follows:

Paritosh Trivedi, Company Secretary & Compliance Officer, signed the disclosure on June 19, 2026.